News

The new facility will allow the company to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The investment in clinical and commercial

Under the deal, BioNTech’s subsidiaries, BioNTech RNA Pharmaceuticals and EUFETS, will work with Siemens to build a fully automated and digitalized production site to provide capacity for BioNTech’s

The company presented the results of a clinical trial comparing Flublok Quadrivalent to a traditional egg-based quadrivalent inactivated vaccine. The data demonstrate superior performance of Flublok based on

The new facility in Cambridge, which will be located at 100 Binney Street in Kendall Square, is expected to open in 2018. The ongoing site expansion in the

While AQX-1125 demonstrated a reduction in pain for patients on AQX-1125 as compared to those patients on placebo following six weeks of treatment, the difference did not reach

PBM will have two representatives on Xalud’s Board of Directors and will also provide operational support to the Company. Xalud Therapeutics is an IND-stage platform gene therapy company

The results were presented in New York City at Stealth’s second Mitochondrial Science and Medicine Series symposium focused on mitochondria’s role in ophthalmology. ReVIEW, a clinical study of

The ARMOR3-SV trial is being carried out for mCRPC patients whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that

The acquisition also creates the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities. The deal was completed through a merger of